‘Waiting Game Continues’ In Emergent BioSolutions, Analysts Cut Price Target
Emergent BioSolutions Inc’s (NYSE:EBS) Q3 sales fell 27% Y/Y to $240 million, missing the consensus of $268.30 million. Revenues from…
MannKind To Rally 57%? Here Are 5 Other Price Target Changes For Wednesday
SVB Leerink raised MannKind Corporation (NASDAQ:MNKD) price target from $5 to $6. . SVB Leerink analyst Thomas Smith…
Emergent BioSolutions Q3 EPS $(1.27) Misses $(0.06) Estimate, Sales $240.00M Miss $268.30M Estimate
Emergent BioSolutions (NYSE:EBS) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of $(0.06) by 2016.67 percent. This is a 252.78 percent decrease over losses of $(0.36) per
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
